Re-splicing of mature mRNA in cancer cells promotes activation of distant weak alternative splice sites

Nucleic Acids Research

Volumn 40, Issue 16, 2012, Pages 7896-7906

  Kameyama, Toshiki ^a   Suzuki, Hitoshi ^b   Mayeda, Akila ^a  

^a FUJITA HEALTH UNIVERSITY   (Japan)

^b JAPAN ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; MESSENGER RNA; MESSENGER RNA PRECURSOR; TUMOR SUSCEPTIBILITY GENE 101 PROTEIN;

ALTERNATIVE RNA SPLICING; ARTICLE; CANCER CELL; CELL STRAIN MCF 7; CONTROLLED STUDY; EXON; EXON SKIPPING; GENE EXPRESSION; PRIORITY JOURNAL; RNA SPLICING; TUMOR SUSCEPTIBILITY GENE 101;

ACID ANHYDRIDE HYDROLASES; ALTERNATIVE SPLICING; CELL LINE, TUMOR; DNA-BINDING PROTEINS; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; EXONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; RNA PRECURSORS; RNA SPLICE SITES; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 84870561895     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gks520     Document Type: Article

References (48)

1. Venables, J.P. (2004) Aberrant and alternative splicing in cancer. Cancer Res., 64, 7647-7654.
2. Kalnina, Z., Zayakin, P., Silina, K. and Line, A. (2005) Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer, 42, 342-357.
3. Pajares, M.J., Ezponda, T., Catena, R., Calvo, A., Pio, R. and Montuenga, L.M. (2007) Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol., 8, 349-357.
4. Li, L. and Cohen, S.N. (1996) Tsg101: a novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell, 85, 319-329.
5. Slagsvold, T., Pattni, K., Malerod, L. and Stenmark, H. (2006) Endosomal and non-endosomal functions of ESCRT proteins. Trends Cell Biol., 16, 317-326.
6. Tanaka, N., Kyuuma, M. and Sugamura, K. (2008) Endosomal sorting complex required for transport proteins in cancer pathogenesis, vesicular transport, and non-endosomal functions. Cancer Sci., 99, 1293-1303.
7. Ohta, M., Inoue, H., Cotticelli, M.G., Kastury, K., Baffa, R., Palazzo, J., Siprashvili, Z., Mori, M., McCue, P., Druck, T. et al. (1996) The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell, 84, 587-597.
8. Barnes, L.D., Garrison, P.N., Siprashvili, Z., Guranowski, A., Robinson, A.K., Ingram, S.W., Croce, C.M., Ohta, M. and Huebner, K. (1996) Fhit, a putative tumor suppressor in humans, is a dinucleoside 50, 50 00-P1, P3-triphosphate hydrolase. Biochemistry, 35, 11529-11535.
9. Hassan, M.I., Naiyer, A. and Ahmad, F. (2010) Fragile histidine triad protein: structure, function, and its association with tumorogenesis. J. Cancer Res. Clin. Oncol., 136, 333-350.
10. Saldivar, J.C., Shibata, H. and Huebner, K. (2010) Pathology and biology associated with the fragile FHIT gene and gene product. J. Cell. Biochem., 109, 858-865.
11. Martin, J., St-Pierre, M.V. and Dufour, J.F. (2011) Hit proteins, mitochondria and cancer. Biochim. Biophys. Acta, 1807, 626-632.
12. Lee, M.P. and Feinberg, A.P. (1997) Aberrant splicing but not mutations of TSG101 in human breast cancer. Cancer Res., 57, 3131-3134.
13. Sun, Z., Pan, J., Bubley, G. and Balk, S.P. (1997) Frequent abnormalities of TSG101 transcripts in human prostate cancer. Oncogene, 15, 3121-3125.
14. Gayther, S.A., Barski, P., Batley, S.J., Li, L., de Foy, K.A., Cohen, S.N., Ponder, B.A. and Caldas, C. (1997) Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours. Oncogene, 15, 2119-2126.
15. Oh, Y., Proctor, M.L., Fan, Y.H., Su, L.K., Hong, W.K., Fong, K.M., Sekido, Y.S., Gazdar, A.F., Minna, J.D. and Mao, L. (1998) TSG101 is not mutated in lung cancer but a shortened transcript is frequently expressed in small cell lung cancer. Oncogene, 17, 1141-1148.
16. Wagner, K.U., Dierisseau, P., Rucker, E.B. III, Robinson, G.W. and Hennighausen, L. (1998) Genomic architecture and transcriptional activation of the mouse and human tumor susceptibility gene TSG101: common types of shorter transcripts are true alternative splice variants. Oncogene, 17, 2761-2770.
17. Ferrer, M., Lopez-Borges, S. and Lazo, P.A. (1999) Expression of a new isoform of the tumor susceptibility TSG101 protein lacking a leucine zipper domain in Burkitt lymphoma cell lines. Oncogene, 18, 2253-2259.
18. Klaes, R., Kloor, M., Willeke, F., Melsheimer, P., von Knebel Doeberitz, M. and Ridder, R. (1999) Significant increase of a specific variant TSG101 transcript during the progression of cervical neoplasia. Eur. J. Cancer, 35, 733-737.
19. Lin, S.F., Lin, P.M., Liu, T.C., Chang, J.G., Sue, Y.C. and Chen, T.P. (2000) Clinical implications of aberrant TSG101 transcripts in acute myeloblastic leukemia. Leuk. Lymphoma, 36, 463-466.
20. McIver, B., Grebe, S.K., Wang, L., Hay, I.D., Yokomizo, A., Liu, W., Goellner, J.R., Grant, C.S., Smith, D.I. and Eberhardt, N.L. (2000) FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance. Clin. Endocrinol., 52, 749-757.
21. Wang, N.M., Chang, J.G., Liu, T.C., Lin, S.F., Peng, C.T., Tsai, F.J. and Tsai, C.H. (2000) Aberrant transcripts of FHIT, TSG101 and PTEN/MMAC1 genes in normal peripheral mononuclear cells. Int. J. Oncol., 16, 75-80.
22. Lee, S.H., Kim, C.J., Park, H.K., Koh, J.W., Cho, M.H., Baek, M.J. and Lee, M.S. (2001) Characterization of aberrant FHIT transcripts in gastric adenocarcinomas. Exp. Mol. Med., 33, 124-130.
23. Matthews, C.P., Shera, K., Kiviat, N. and McDougall, J.K. (2001) Expression of truncated FHIT transcripts in cervical cancers and in normal human cells. Oncogene, 20, 4665-4675.
24. Kraggerud, S.M., Aman, P., Holm, R., Stenwig, A.E., Fossa, S.D., Nesland, J.M. and Lothe, R.A. (2002) Alterations of the fragile histidine triad gene, FHIT, and its encoded products contribute to testicular germ cell tumorigenesis. Cancer Res., 62, 512-517.
25. Roca, X., Sachidanandam, R. and Krainer, A.R. (2005) Determinants of the inherent strength of human 50 splice sites. RNA, 11, 683-698.
26. Sahashi, K., Masuda, A., Matsuura, T., Shinmi, J., Zhang, Z., Takeshima, Y., Matsuo, M., Sobue, G. and Ohno, K. (2007) In vitro and in silico analysis reveals an efficient algorithm to predict the splicing consequences of mutations at the 50 splice sites. Nucleic Acids Res., 35, 5995-6003.
27. Hartmann, L., Theiss, S., Niederacher, D. and Schaal, H. (2008) Diagnostics of pathogenic splicing mutations: does bioinformatics cover all bases? Front. Biosci., 13, 3252-3272.
28. Niwa, H., Yamamura, K. and Miyazaki, J. (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene, 108, 193-199.
29. Suzuki, H., Zuo, Y., Wang, J., Zhang, M.Q., Malhotra, A. and Mayeda, A. (2006) Characterization of RNase R-digested cellular RNA source that consists of lariat and circular RNAs from pre-mRNA splicing. Nucleic Acids Res., 34, e63.
30. Zheng, C.L., Kwon, Y.S., Li, H.R., Zhang, K., Coutinho-Mansfield, G., Yang, C., Nair, T.M., Gribskov, M. and Fu, X.D. (2005) MAASE: an alternative splicing database designed for supporting splicing microarray applications. RNA, 11, 1767-1776.
31. Roca, X., Sachidanandam, R. and Krainer, A.R. (2003) Intrinsic differences between authentic and cryptic 50 splice sites. Nucleic Acids Res., 31, 6321-6333.
32. Vorechovsky, I. (2006) Aberrant 30 splice sites in human disease genes: mutation pattern, nucleotide structure and comparison of computational tools that predict their utilization. Nucleic Acids Res., 34, 4630-4641.
33. Liu, R.T., Huang, C.C., You, H.L., Chou, F.F., Hu, C.C., Chao, F.P., Chen, C.M. and Cheng, J.T. (2002) Overexpression of tumor susceptibility gene TSG101 in human papillary thyroid carcinomas. Oncogene, 21, 4830-4837.
34. Young, T.W., Rosen, D.G., Mei, F.C., Li, N., Liu, J., Wang, X.F. and Cheng, X. (2007) Up-regulation of tumor susceptibility gene 101 conveys poor prognosis through suppression of p21 expression in ovarian cancer. Clin. Cancer Res., 13, 3848-3854.
35. Oh, K.B., Stanton, M.J., West, W.W., Todd, G.L. and Wagner, K.U. (2007) Tsg101 is upregulated in a subset of invasive human breast cancers and its targeted overexpression in transgenic mice reveals weak oncogenic properties for mammary cancer initiation. Oncogene, 26, 5950-5959.
36. Ma, X.R., Edmund Sim, U.H., Pauline, B., Patricia, L. and Rahman, J. (2008) Overexpression of WNT2 and TSG101 genes in colorectal carcinoma. Trop. Biomed., 25, 46-57.
37. Liu, D.C., Yang, Z.L. and Jiang, S. (2011) Identification of PEG10 and TSG101 as carcinogenesis, progression, and poor-prognosis related biomarkers for gallbladder adenocarcinoma. Pathol. Oncol. Res., 17, 859-866.
38. Wagner, K.U., Dierisseau, P., Rucker, E.B. III, Robinson, G.W. and Hennighausen, L. (1998) Genomic architecture and transcriptional activation of the mouse and human tumor susceptibility gene TSG101: common types of shorter transcripts are true alternative splice variants. Oncogene, 17, 2761-2770.
39. Wagner, K.U., Dierisseau, P. and Hennighausen, L. (1999) Assignment of the murine tumor susceptibility gene 101 (tsg101) and a processed tsg101 pseudogene (tsg101-ps1) to mouse chromosome 7 band B5 and chromosome 15 band D1 by in situ hybridization. Cytogenet. Cell Genet., 84, 87-88.
40. Xie, W., Li, L. and Cohen, S.N. (1998) Cell cycle-dependent subcellular localization of the TSG101 protein and mitotic and nuclear abnormalities associated with TSG101 deficiency. Proc. Natl Acad. Sci. USA, 95, 1595-1600.
41. Vogel, J., Hess, W.R. and Borner, T. (1997) Precise branch point mapping and quantification of splicing intermediates. Nucleic Acids Res., 25, 2030-2031.
42. Burnette, J.M., Miyamoto-Sato, E., Schaub, M.A., Conklin, J. and Lopez, A.J. (2005) Subdivision of large introns in Drosophila by recursive splicing at nonexonic elements. Genetics, 170, 661-674.
43. Conklin, J.F., Goldman, A. and Lopez, A.J. (2005) Stabilization and analysis of intron lariats in vivo. Methods, 37, 368-375.
44. Hatton, A.R., Subramaniam, V. and Lopez, A.J. (1998) Generation of alternative Ultrabithorax isoforms and stepwise removal of a large intron by resplicing at exon-exon junctions. Mol. Cell, 2, 787-796.
45. Zhang, C., Hastings, M.L., Krainer, A.R. and Zhang, M.Q. (2007) Dual-specificity splice sites function alternatively as 50 and 30 splice sites. Proc. Natl Acad. Sci. USA, 104, 15028-15033.
46. Parra, M.K., Tan, J.S., Mohandas, N. and Conboy, J.G. (2008) Intrasplicing coordinates alternative first exons with alternative splicing in the protein 4.1R gene. EMBO J., 27, 122-131.
47. Srebrow, A. and Kornblihtt, A.R. (2006) The connection between splicing and cancer. J. Cell Sci., 119, 2635-2641.
48. Gao, K., Masuda, A., Matsuura, T. and Ohno, K. (2008) Human branch point consensus sequence is yUnAy. Nucleic Acids Res., 36, 2257-2267.